Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes
暂无分享,去创建一个
A. Savic | P. Fenaux | E. Hellström-Lindberg | U. Germing | A. Symeonidis | I. Kotsianidis | R. Itzykson | L. Malcovati | D. Bowen | J. Čermák | M. Mittelman | R. Stauder | T. D. de Witte | K. Mądry | S. Langemeijer | G. Sanz | O. Beyne-Rauzy | N. Blijlevens | M. Holm | D. Culligan | Alex G Smith | S. Crouch | A. Almeida | M. Hoeks | A. Guerci-Bresler | C. V. van Marrewijk | A. Tatic | N. Gredelj-Šimec | L. de Swart | Alex Smith
[1] G. Garcia-Manero,et al. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. , 2019, Blood.
[2] D. Cooper,et al. Effect of age of red cells for transfusion on patient outcomes: a systematic review and meta-analysis. , 2018, Transfusion medicine reviews.
[3] D. Swinkels,et al. Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes , 2017, Haematologica.
[4] J. Reynolds,et al. Dynamic assessment of RBC‐transfusion dependency improves the prognostic value of the revised‐IPSS in MDS patients , 2017, American journal of hematology.
[5] Donald J. McMahon,et al. Prolonged red cell storage before transfusion increases extravascular hemolysis , 2017, The Journal of clinical investigation.
[6] W. Jędrzejczak,et al. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry. , 2016, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.
[7] D. Swinkels,et al. Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders , 2016, Haematologica.
[8] P. Fenaux,et al. Validation of the revised international prognostic scoring system (IPSS‐R) in patients with lower‐risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry , 2015, British journal of haematology.
[9] R. M. de Freitas,et al. HFE gene mutation and oxidative damage biomarkers in patients with myelodysplastic syndromes and its relation to transfusional iron overload: an observational cross-sectional study , 2015, BMJ Open.
[10] L. Hofbauer,et al. Myelodysplasia is in the niche: novel concepts and emerging therapies , 2014, Leukemia.
[11] A. Verma,et al. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. , 2014, Blood.
[12] U. Germing,et al. Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome , 2013, Annals of Hematology.
[13] P. Campbell,et al. Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1 , 2013, Haematologica.
[14] P. Fenaux,et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes , 2012, Haematologica.
[15] S. Sheth,et al. Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron. , 2011, Blood.
[16] M. Cazzola,et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.
[17] K. Saigo,et al. Oxidative Stress Levels in Myelodysplastic Syndrome Patients: Their Relationship to Serum Ferritin and Haemoglobin Values , 2011, The Journal of international medical research.
[18] M. Cazzola,et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) , 2011, Haematologica.
[19] A. Carrió,et al. Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support , 2011, American journal of hematology.
[20] D. Girelli,et al. Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes , 2010, PloS one.
[21] T. Barbui,et al. What are RBC-transfusion-dependence and -independence? , 2011, Leukemia research.
[22] M. Laouri,et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Ning Zhang,et al. Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation. , 2010, Blood.
[24] Raffaella Origa,et al. BETA THALASSEMIA , 2018, The Professional Medical Journal.
[25] D. Swinkels,et al. Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome , 2010, British journal of haematology.
[26] N. Gattermann,et al. Iron overload in MDS—pathophysiology, diagnosis, and complications , 2010, Annals of Hematology.
[27] W. D. de Grip,et al. Survival of red blood cells after transfusion: a comparison between red cells concentrates of different storage periods , 2008, Transfusion.
[28] E. Fibach,et al. Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome , 2007, European journal of haematology.
[29] M. Cazzola,et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Brand,et al. Effects of storage time of red blood cell transfusions on the prognosis of coronary artery bypass graft patients , 2006, Transfusion.
[31] S. Rivella,et al. Role of Iron in Inducing Oxidative Stress in Thalassemia: Can It Be Prevented by Inhibition of Absorption and by Antioxidants? , 2005, Annals of the New York Academy of Sciences.
[32] Luca Malcovati,et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] M. Cazzola,et al. Myelodysplastic syndromes--coping with ineffective hematopoiesis. , 2005, The New England journal of medicine.
[34] N. Harris,et al. The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.
[35] G. Link,et al. Pathophysiology of Iron Overload a , 1998, Annals of the New York Academy of Sciences.
[36] P. Greenberg,et al. Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model , 1997, British journal of haematology.
[37] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.